James Hardie Industries (JHX) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
20 May, 2026Executive summary
Q4 FY26 net sales reached $1.4 billion, up 45% year-over-year, driven by the AZEK acquisition, while organic net sales declined 1%.
Full-year FY26 net sales were $4.84 billion, up 25% year-over-year, with organic net sales down 2%.
Adjusted EBITDA for Q4 FY26 was $381 million (27.1% margin), with full-year Adjusted EBITDA at $1.27 billion (26.2% margin).
Integration of AZEK progressing well, with cost synergies ahead of schedule and commercial synergies on track; $37 million in cost synergies delivered in FY26, targeting $125 million in three years.
Challenging market conditions included weather disruptions, declining construction activity, and economic uncertainty, but strong execution on cost control, pricing, and customer service drove margin improvements.
Financial highlights
Q4 FY26 net sales grew 45% to $1.4 billion, including $445 million from AZEK; organic net sales declined 1%.
Full-year FY26 net sales up 25% to $4.84 billion; organic net sales down 2%.
Q4 FY26 adjusted EBITDA $381 million (27.1% margin); full-year adjusted EBITDA $1.27 billion (26.2% margin).
Free cash flow for FY26 was $314 million, with FY27 expected to exceed $500 million.
Q4 FY26 adjusted net income $172.6 million (+11%); adjusted diluted EPS $0.30 (-19%).
Outlook and guidance
FY27 net sales guidance: $5.25–$5.41 billion; Siding & Trim: $3.04–$3.13 billion; Deck, Rail & Accessories: $1.11–$1.15 billion.
FY27 adjusted EBITDA guidance: $1.45–$1.5 billion (4.1–7.7% pro forma growth).
FY27 free cash flow expected to exceed $500 million, up over $200 million year-over-year.
Q1 FY27 net sales guidance: $1.32–$1.35 billion; adjusted EBITDA $354–$375 million.
Market expected to decline ~3% in 2027; guidance assumes no improvement in macro conditions.
Latest events from James Hardie Industries
- Record Q1 EBITDA and 4% sales growth achieved; FY25 guidance reaffirmed amid market headwinds.JHX
Q1 20258 Jul 2026 - Shareholders will vote on board, pay, auditor, and governance changes after a year of major transformation.JHX
Proxy filing1 Jul 2026 - Director elections, say-on-pay, auditor ratification, and governance amendments up for vote.JHX
Proxy filing1 Jul 2026 - Major acquisition, board refresh, and executive pay overhaul highlight FY26 governance and strategy.JHX
Proxy filing18 Jun 2026 - Net sales up 30% to $1.24B, with higher EBITDA and raised FY26 guidance amid synergy progress.JHX
Q3 202613 Apr 2026 - Q2 FY26 sales jumped 34% on AZEK deal; margins fell, but FY26 outlook and synergies improved.JHX
Q2 20263 Feb 2026 - H1 EBITDA topped $500m, FY25 guidance and buybacks raised despite lower sales.JHX
Q2 202514 Jan 2026 - FY25 met guidance; AZEK deal to drive $500M synergies; FY26 targets sales, EBITDA, and cash flow growth.JHX
Q4 202514 Jan 2026 - Q3 FY25 delivered resilient margins, reaffirmed growth plans, and launched a new buyback program.JHX
Q3 20258 Jan 2026